ClinicalTrials.gg
CompletedNCT07214935Updated Nov 13, 2025Results posted

A TQT Study of Effect of M2951 on Cardiac Repolarization

A Phase 1 interventional study of Placebo matched to M2951 and Moxifloxacin in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Nov 2022, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).

02

Conditions studied

  • Healthy

Keywords

  • M2951
  • Bruton's Tyrosine Kinase
  • Cardiac Repolarization
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are overtly healthy as determined by medical evaluation, including no abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Participants have a body weight within 50.0 and 100.0 kilograms (kg) (inclusive) and (BMI) within the range 19.0 and 30.0 kilograms per square meter (kg/m\^2) (inclusive)
  • Participants are stable nonsmokers for at least 3 months preceding the first administration of study intervention

Exclusion criteria

Exclusion Criteria:

  • Participants with history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation, and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation
  • Participants with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study. Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to the first administration of study intervention
  • Participants with history of any
  • Participants with history of seizures
  • Participants with history of pharmacologically treated psychiatric disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Participants will receive one of the four interventions in a sequence decided at randomization.

    Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose

  • Experimental
    Treatment Sequence 2

    Participants will receive one of the four interventions in a sequence decided at randomization.

    Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose

  • Experimental
    Treatment Sequence 3

    Participants will receive one of the four interventions in a sequence decided at randomization.

    Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose

  • Experimental
    Treatment Sequence 4

    Participants will receive one of the four interventions in a sequence decided at randomization.

    Drug: Placebo matched to M2951 · Drug: Moxifloxacin · Drug: M2951 Low Dose · Drug: M2951 High Dose

Interventions

  • DrugPlacebo matched to M2951

    Participants will receive single oral dose of placebo matched to M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

  • Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

  • Participants will receive single oral low dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

    Also known as: Evobrutinib, MSC2364447C

  • Participants will receive single oral high dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

    Also known as: Evobrutinib, MSC2364447C

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib

    A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.

    Time frame: Baseline and from 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours

Secondary outcomes

  1. Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin

    A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.

    Time frame: From 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.

    Time frame: Up to 3 months

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity

    Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories: 1\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.

    Time frame: Up to 3 months

  4. Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests

    The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.

    Time frame: Up to Day 29

  5. Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs

    Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

    Time frame: Up to Day 29

  6. Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings

    The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.

    Time frame: Up to Day 29

  7. Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib

    AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  8. Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib

    The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  9. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib

    Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  10. Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib

    Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  11. Apparent Terminal Half-life (t1/2) of Evobrutinib

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  12. Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin

    AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  13. Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin

    Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  14. Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin

    The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  15. Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin

    Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22

  16. Effect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate

    The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  17. Effect of Evobrutinib on ECG Parameters: RR Interval

    The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  18. Effect of Evobrutinib on ECG Parameters: QT Interval

    The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  19. Effect of Evobrutinib on ECG Parameters: QTcF Interval

    The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  20. Effect of Evobrutinib on ECG Parameters: QTcP Interval

    The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  21. Effect of Evobrutinib on ECG Parameters: PR Interval

    The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

  22. Effect of Evobrutinib on ECG Parameters: QRS Duration

    The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

    Time frame: Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours

07

Results

Posted Nov 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started9999
Completed7788
Not completed2211
Withdrew: Adverse event1110
Withdrew: Lost to follow-up0100
Withdrew: Participant did not meet all eligibility criteria, admission drug screen positive1000
Withdrew: Participant discontinued prior to first dosing0001

Outcome measures

PrimaryPlacebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib

A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.

Time frame:
Baseline and from 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours
Reported as:
Geometric mean · milliseconds
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib
millisecondsEvobrutinib 45mgEvobrutinib 225mg
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib-1.62 (-2.15 to -1.09)-2.28 (-3.63 to -0.93)
SecondaryPlacebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin

A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.

Time frame:
From 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours
Reported as:
Geometric mean · milliseconds
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin
millisecondsMoxifloxacin 400mg
Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin12.2 (10.3 to 14.1)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.

Time frame:
Up to 3 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)8558
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity

Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories: 1\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.

Time frame:
Up to 3 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity
ParticipantsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity0000
SecondaryNumber of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests

The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests
ParticipantsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests0000
SecondaryNumber of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs

Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs
ParticipantsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings

The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings
ParticipantsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings0000
SecondaryArea Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · hour*nanogram/milliliter
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib
hour*nanogram/milliliterEvobrutinib 45mgEvobrutinib 225mg
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib249 ± 38.41420 ± 37.5
SecondaryArea Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib
h*ng/mLEvobrutinib 45mgEvobrutinib 225mg
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib248 ± 38.41420 ± 37.5
SecondaryMaximum Observed Plasma Concentration (Cmax) of Evobrutinib

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
ng/mLEvobrutinib 45mgEvobrutinib 225mg
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib123 ± 45.8670 ± 51.3
SecondaryTime to Reach Maximum Blood Concentration (Tmax) of Evobrutinib

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Median · hours
Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib
hoursEvobrutinib 45mgEvobrutinib 225mg
Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib0.500 (0.267 to 2.02)0.500 (0.250 to 2.03)
SecondaryApparent Terminal Half-life (t1/2) of Evobrutinib

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · hours
Apparent Terminal Half-life (t1/2) of Evobrutinib
hoursEvobrutinib 45mgEvobrutinib 225mg
Apparent Terminal Half-life (t1/2) of Evobrutinib1.32 ± 22.72.09 ± 33.8
SecondaryArea Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · h*ng/mL
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin
h*ng/mLMoxifloxacin 400mg
Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin19600 ± 19.6
SecondaryMaximum Observed Plasma Concentration (Cmax) of Moxifloxacin

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin
ng/mLMoxifloxacin 400mg
Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin2000 ± 30.3
SecondaryArea Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin
h*ng/mLMoxifloxacin 400mg
Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin24900 ± 19.8
SecondaryTime to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22
Reported as:
Median · hours
Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin
hoursMoxifloxacin 400mg
Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin1.50 (0.250 to 4.00)
SecondaryEffect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate

The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · beats/min
Effect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate
beats/minEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline58.1 ± 8.3858.6 ± 7.3858.7 ± 7.9057.9 ± 7.61
15 Minutes Post-dose0.6 ± 3.261.3 ± 3.830.0 ± 2.580.8 ± 2.65
30 Minutes Post-dose0.0 ± 3.430.2 ± 3.261.6 ± 3.570.7 ± 2.98
1 Hour Post-dose1.7 ± 3.681.0 ± 4.002.6 ± 3.803.2 ± 4.10
1.5 Hour Post-dose1.7 ± 3.261.1 ± 3.603.0 ± 3.483.9 ± 4.03
2 Hour Post-dose0.6 ± 3.101.4 ± 2.213.6 ± 4.762.8 ± 3.05
2.5 Hour Post-dose0.4 ± 4.040.7 ± 3.731.9 ± 4.221.2 ± 3.64
3 Hour Post-dose-0.4 ± 4.43-0.0 ± 3.282.4 ± 3.631.9 ± 4.13
4 Hour Post-dose0.8 ± 3.670.8 ± 3.542.7 ± 6.522.7 ± 4.03
6 Hour Post-dose6.6 ± 6.426.1 ± 4.857.8 ± 4.849.3 ± 5.53
8 Hour Post-dose4.2 ± 5.852.3 ± 5.295.5 ± 4.245.2 ± 5.30
12 Hour Post-dose1.3 ± 5.36-0.1 ± 4.632.6 ± 5.620.7 ± 4.75
16 Hour Post-dose3.5 ± 5.912.1 ± 5.734.6 ± 5.255.6 ± 5.16
24 Hour Post-dose6.0 ± 7.882.6 ± 5.624.3 ± 5.385.3 ± 5.69
SecondaryEffect of Evobrutinib on ECG Parameters: RR Interval

The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: RR Interval
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline1057.4 ± 146.411044.0 ± 139.391043.4 ± 144.031056.1 ± 140.61
15 Minutes Post-dose-14.8 ± 60.09-24.4 ± 63.480.6 ± 45.64-13.8 ± 54.73
30 Minutes Post-dose-4.2 ± 65.10-4.9 ± 55.65-26.6 ± 66.04-11.3 ± 48.52
1 Hour Post-dose-30.2 ± 72.81-17.0 ± 60.28-40.3 ± 62.87-47.3 ± 58.95
1.5 Hour Post-dose-34.4 ± 65.46-17.2 ± 59.43-52.5 ± 59.00-66.0 ± 78.10
2 Hour Post-dose-14.0 ± 57.06-26.2 ± 40.34-65.0 ± 81.34-49.9 ± 57.51
2.5 Hour Post-dose-10.8 ± 69.18-10.6 ± 70.27-37.4 ± 79.84-18.8 ± 65.83
3 Hour Post-dose0.2 ± 80.54-1.8 ± 65.55-45.2 ± 74.46-31.8 ± 81.31
4 Hour Post-dose-20.1 ± 67.37-15.9 ± 61.57-48.1 ± 99.08-44.6 ± 71.37
6 Hour Post-dose-112.1 ± 115.18-101.1 ± 94.08-127.3 ± 89.62-146.5 ± 94.86
8 Hour Post-dose-74.0 ± 95.45-38.8 ± 95.45-97.8 ± 83.82-83.7 ± 88.55
12 Hour Post-dose-24.8 ± 94.781.4 ± 89.18-47.3 ± 103.93-15.7 ± 93.15
16 Hour Post-dose-61.3 ± 98.99-39.9 ± 105.20-83.3 ± 99.08-94.7 ± 84.41
24 Hour Post-dose-98.8 ± 127.77-42.6 ± 106.76-74.0 ± 101.40-85.1 ± 88.69
SecondaryEffect of Evobrutinib on ECG Parameters: QT Interval

The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: QT Interval
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline395.8 ± 28.44393.2 ± 27.84394.5 ± 26.29396.4 ± 27.77
15 Minutes Post-dose-0.1 ± 6.99-1.5 ± 6.700.1 ± 6.341.2 ± 8.39
30 Minutes Post-dose0.6 ± 8.71-0.5 ± 5.61-1.7 ± 7.290.1 ± 7.44
1 Hour Post-dose-5.2 ± 8.86-2.8 ± 7.993.6 ± 10.74-5.0 ± 9.08
1.5 Hour Post-dose-8.0 ± 8.12-6.0 ± 8.933.2 ± 10.41-8.2 ± 11.75
2 Hour Post-dose-4.3 ± 7.63-6.9 ± 6.623.5 ± 13.02-7.4 ± 10.21
2.5 Hour Post-dose-4.5 ± 9.55-5.4 ± 9.465.5 ± 11.71-4.1 ± 10.14
3 Hour Post-dose-3.5 ± 10.58-3.6 ± 9.315.3 ± 12.19-6.0 ± 12.45
4 Hour Post-dose-5.7 ± 9.95-4.4 ± 10.672.4 ± 16.10-7.8 ± 10.66
6 Hour Post-dose-19.2 ± 15.98-16.9 ± 13.10-13.6 ± 13.12-22.3 ± 14.43
8 Hour Post-dose-13.7 ± 13.06-11.3 ± 13.33-8.2 ± 12.25-14.2 ± 12.80
12 Hour Post-dose-2.7 ± 14.12-0.7 ± 13.231.4 ± 14.28-1.7 ± 12.04
16 Hour Post-dose-4.1 ± 14.04-0.8 ± 15.15-0.9 ± 13.19-8.5 ± 13.26
24 Hour Post-dose-16.3 ± 18.95-9.5 ± 13.66-8.5 ± 13.92-15.8 ± 12.30
SecondaryEffect of Evobrutinib on ECG Parameters: QTcF Interval

The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: QTcF Interval
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline389.4 ± 18.08388.4 ± 17.88389.8 ± 17.28390.0 ± 17.58
15 Minutes Post-dose1.6 ± 4.501.6 ± 4.66-0.1 ± 3.912.8 ± 3.75
30 Minutes Post-dose0.8 ± 5.080.0 ± 3.771.8 ± 5.901.6 ± 4.26
1 Hour Post-dose-1.2 ± 4.49-0.7 ± 4.628.8 ± 7.141.3 ± 5.16
1.5 Hour Post-dose-3.7 ± 4.50-3.8 ± 5.049.8 ± 8.090.2 ± 5.46
2 Hour Post-dose-2.7 ± 3.77-3.6 ± 3.9811.7 ± 7.92-1.1 ± 5.61
2.5 Hour Post-dose-3.3 ± 5.26-3.9 ± 4.8710.0 ± 6.33-1.7 ± 4.52
3 Hour Post-dose-3.7 ± 5.89-3.4 ± 4.6410.8 ± 5.78-1.9 ± 5.29
4 Hour Post-dose-3.3 ± 5.34-2.4 ± 5.808.4 ± 7.03-2.0 ± 5.54
6 Hour Post-dose-5.0 ± 7.51-4.0 ± 7.073.0 ± 8.24-3.4 ± 7.51
8 Hour Post-dose-4.5 ± 5.64-6.2 ± 7.414.2 ± 8.00-3.4 ± 7.85
12 Hour Post-dose0.2 ± 6.32-0.8 ± 5.887.2 ± 8.940.1 ± 4.51
16 Hour Post-dose3.6 ± 8.143.8 ± 7.799.6 ± 6.993.7 ± 6.89
24 Hour Post-dose-3.8 ± 8.18-4.1 ± 6.160.9 ± 6.97-4.9 ± 6.05
SecondaryEffect of Evobrutinib on ECG Parameters: QTcP Interval

The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: QTcP Interval
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline388.2 ± 17.69387.5 ± 17.40389.1 ± 17.18388.9 ± 17.08
15 Minutes Post-dose1.9 ± 5.212.1 ± 5.54-0.1 ± 4.063.2 ± 3.71
30 Minutes Post-dose0.8 ± 5.510.1 ± 4.572.5 ± 6.651.9 ± 4.32
1 Hour Post-dose-0.6 ± 4.91-0.3 ± 5.159.8 ± 7.302.5 ± 5.47
1.5 Hour Post-dose-3.1 ± 4.95-3.4 ± 5.1810.9 ± 8.351.7 ± 5.45
2 Hour Post-dose-2.4 ± 4.06-3.1 ± 3.9413.0 ± 8.26-0.1 ± 5.33
2.5 Hour Post-dose-3.1 ± 5.59-3.7 ± 5.2010.7 ± 6.57-1.3 ± 4.45
3 Hour Post-dose-3.7 ± 6.33-3.5 ± 4.6011.7 ± 5.43-1.2 ± 5.18
4 Hour Post-dose-2.9 ± 5.43-2.0 ± 5.719.4 ± 6.86-1.0 ± 5.65
6 Hour Post-dose-2.6 ± 7.96-1.7 ± 7.465.8 ± 8.54-0.0 ± 7.63
8 Hour Post-dose-3.0 ± 6.12-5.2 ± 7.826.3 ± 8.36-1.4 ± 8.29
12 Hour Post-dose0.8 ± 6.20-0.9 ± 5.908.2 ± 9.620.3 ± 4.98
16 Hour Post-dose4.9 ± 8.654.5 ± 8.1011.3 ± 7.535.8 ± 7.07
24 Hour Post-dose-1.5 ± 8.22-3.2 ± 6.862.5 ± 7.33-2.9 ± 6.47
SecondaryEffect of Evobrutinib on ECG Parameters: PR Interval

The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: PR Interval
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline166.7 ± 16.59170.4 ± 17.93167.7 ± 17.73167.1 ± 17.99
15 Minutes Post-dose-0.2 ± 4.66-1.2 ± 5.29-0.8 ± 4.01-1.3 ± 4.36
30 Minutes Post-dose0.5 ± 3.722.6 ± 4.37-1.2 ± 5.270.1 ± 5.14
1 Hour Post-dose1.1 ± 4.131.2 ± 4.04-1.5 ± 7.52-0.8 ± 5.11
1.5 Hour Post-dose1.9 ± 5.110.9 ± 5.15-1.9 ± 7.41-0.9 ± 5.69
2 Hour Post-dose0.9 ± 4.91-0.5 ± 3.59-2.5 ± 8.15-0.3 ± 5.24
2.5 Hour Post-dose0.6 ± 4.64-1.8 ± 5.20-3.5 ± 6.49-1.4 ± 6.69
3 Hour Post-dose0.1 ± 5.69-1.5 ± 5.45-3.7 ± 7.42-3.0 ± 5.16
4 Hour Post-dose-0.5 ± 7.11-1.2 ± 5.01-3.6 ± 7.77-4.2 ± 4.16
6 Hour Post-dose-9.3 ± 7.52-9.4 ± 4.73-10.6 ± 8.22-11.1 ± 8.48
8 Hour Post-dose-8.3 ± 6.98-9.3 ± 6.53-9.3 ± 7.30-11.1 ± 7.17
12 Hour Post-dose-2.2 ± 7.43-3.9 ± 8.28-3.6 ± 8.03-2.8 ± 6.28
16 Hour Post-dose-2.6 ± 8.70-5.2 ± 7.20-3.1 ± 7.95-4.1 ± 6.25
24 Hour Post-dose-1.0 ± 7.00-2.6 ± 6.14-0.5 ± 9.38-1.2 ± 7.99
SecondaryEffect of Evobrutinib on ECG Parameters: QRS Duration

The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Time frame:
Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours
Reported as:
Mean · milliseconds
Effect of Evobrutinib on ECG Parameters: QRS Duration
millisecondsEvobrutinib 45mgEvobrutinib 225mgMoxifloxacin 400mgPlacebo
Baseline91.7 ± 8.2891.8 ± 8.2491.7 ± 8.1191.0 ± 8.12
15 Minutes Post-dose0.1 ± 1.440.3 ± 1.150.1 ± 1.310.4 ± 1.23
30 Minutes Post-dose0.4 ± 1.250.4 ± 1.41-0.4 ± 1.220.7 ± 1.44
1 Hour Post-dose-0.1 ± 1.200.4 ± 1.020.2 ± 1.260.5 ± 1.29
1.5 Hour Post-dose-0.4 ± 1.30-0.2 ± 1.29-0.1 ± 1.16-0.1 ± 1.15
2 Hour Post-dose-0.5 ± 1.17-0.6 ± 1.47-0.1 ± 1.42-0.5 ± 1.60
2.5 Hour Post-dose-0.6 ± 1.29-0.3 ± 1.64-0.2 ± 1.27-0.3 ± 1.59
3 Hour Post-dose-0.5 ± 1.35-0.1 ± 1.50-0.1 ± 1.03-0.1 ± 1.35
4 Hour Post-dose-0.7 ± 1.41-0.3 ± 1.71-0.4 ± 1.700.0 ± 1.53
6 Hour Post-dose-0.6 ± 2.26-0.5 ± 2.12-0.6 ± 1.70-0.4 ± 1.98
8 Hour Post-dose-0.8 ± 1.99-0.5 ± 1.78-0.1 ± 1.820.4 ± 1.97
12 Hour Post-dose-0.2 ± 1.950.2 ± 2.140.2 ± 1.450.2 ± 1.85
16 Hour Post-dose0.0 ± 1.910.4 ± 1.740.6 ± 1.900.8 ± 2.08
24 Hour Post-dose0.5 ± 1.930.1 ± 1.220.3 ± 1.310.5 ± 1.43

Adverse events

Collected over Up to 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/32 (0%)0/32 (0%)8/32 (25%)
400 mg Moxifloxacin0/32 (0%)0/32 (0%)5/32 (15.6%)
45 mg Evobrutinib0/31 (0%)0/31 (0%)8/31 (25.8%)
225 mg Evobrutinib0/32 (0%)0/32 (0%)5/32 (15.6%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo400 mg Moxifloxacin45 mg Evobrutinib225 mg Evobrutinib
HeadacheNervous system disorders4/323/321/310/32
Atrioventricular block second degreeCardiac disorders1/320/321/310/32
Ventricular tachycardiaCardiac disorders0/320/321/311/32
ConjunctivitisInfections and infestations0/320/321/310/32
NasopharyngitisInfections and infestations0/320/321/310/32
Back painMusculoskeletal and connective tissue disorders0/320/321/311/32
Pain in extremityMusculoskeletal and connective tissue disorders0/320/321/310/32
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/320/321/310/32
Ventricular extrasystolesCardiac disorders1/320/320/311/32
DiarrhoeaGastrointestinal disorders1/320/320/310/32

Baseline characteristics

The safety analysis set included all participants who were administered any dose of any study intervention.

Age, Continuous
Age, Continuous(Years)Sequence 1Sequence 2Sequence 3Sequence 4Total
Mean45 ± 7.536 ± 10.441 ± 8.640 ± 11.341 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Female32218
Male677727
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Hispanic or Latino00000
Not Hispanic or Latino999835
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American11002
White888832
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Aug 2023, 9 months.

Results were first posted in Nov 2025, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 9, 2025
StartActual
Nov 8, 2022
Primary completionActual
Aug 25, 2023
CompletionActual
Aug 25, 2023
Results first posted
Nov 13, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07214935
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Nov 8, 2022
Primary completion
Aug 25, 2023
Completion
Aug 25, 2023
Results posted
Nov 13, 2025
Last update
Nov 13, 2025

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion